Trial Profile
An investigator-sponsored paediatric trial of MOR-208 in combination with an immune cell transplantation for Acute-lymphoblastic-leukaemia
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 14 Sep 2015
Price :
$35
*
At a glance
- Drugs Tafasitamab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 Sep 2015 According to Morpho Sys media release, company is planning to start enrolment in the first half of 2016.
- 12 Mar 2015 New trial record